These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 14619487)

  • 21. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
    Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
    Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer.
    Tsujitani S; Kakeji Y; Orita H; Watanabe A; Kohnoe S; Baba H; Anai H; Maehara Y; Sugimachi K
    Anticancer Res; 1992; 12(3):645-8. PubMed ID: 1622120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses.
    Faith A; Peek E; McDonald J; Urry Z; Richards DF; Tan C; Santis G; Hawrylowicz C
    Am J Respir Cell Mol Biol; 2007 Mar; 36(3):360-7. PubMed ID: 17023687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
    Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
    Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.